HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease

Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT00243724
Collaborator
(none)
350
10
26
35
1.3

Study Details

Study Description

Brief Summary

Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
350 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open-Label, Parallel-Group, Multi-Centre Study to Determine the Effect of Treatment With Esomeprazole for Six Months on Histological Markers of Esophageal Epithelial Acid-Related Disease in Patients With Upper GI Symptoms.
Study Start Date :
Apr 1, 2005
Actual Primary Completion Date :
Jun 1, 2007
Actual Study Completion Date :
Jun 1, 2007

Outcome Measures

Primary Outcome Measures

  1. Change from baseline after 6 months in the level of ki-67 expression and histological markers of esophageal epithelial acid-related disease after acid-suppressive therapy with esomeprazole []

Secondary Outcome Measures

  1. Changes in immunohistochemical markers of esophageal epithelial acid-related disease after 6 months treatment with different levels of acid suppression with esomeprazole []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Signed informed consent

  • 18 years or older

  • history of upper GI symptoms

Exclusion Criteria:
  • Peptic ulcer disease

  • upper gastrointestinal surgery

  • malignancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Research Site Vancouver British Columbia Canada
2 Research Site Halifax Nova Scotia Canada
3 Research Site Guelph Ontario Canada
4 Research Site Hamilton Ontario Canada
5 Research Site Kingston Ontario Canada
6 Research Site Mississauga Ontario Canada
7 Research Site North York Ontario Canada
8 Research Site Montreal Quebec Canada
9 Research Site Pointe-Claire Quebec Canada
10 Research Site Quebec Canada

Sponsors and Collaborators

  • AstraZeneca

Investigators

  • Study Director: AstraZeneca Canada Medical Director, MD, AstraZeneca

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00243724
Other Study ID Numbers:
  • D9612L00078
First Posted:
Oct 25, 2005
Last Update Posted:
Mar 26, 2009
Last Verified:
Mar 1, 2009

Study Results

No Results Posted as of Mar 26, 2009